Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions

Magaret, Amalia, Jacob, Shevin ORCID: https://orcid.org/0000-0003-2425-9394, Halloran, M. Elizabeth, Guthrie, Katherine A, Magaret, Craig A, Johnston, Christine, Simon, Noah R and Wald, Anna (2020) 'Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions'. Annals of Internal Medicine, Vol 173, Issue 7, pp. 576-577.

Text Magaret Coronavirus 2020June05 clean.docx - Accepted Version Download (38kB)

Abstract

We propose platform trials with outcome-adaptive randomization to efficiently select the most effective coronavirus disease 2019 (COVID-19) treatments. The global spread of severe acute respiratory syndrome coronavirus 2 infection is alarming in its geographic scope and in the number of associated deaths. There are currently no treatments proven to decrease mortality from COVID-19 further than what can be achieved through supportive care. Thus far, the choice of therapeutics has been limited to existing, repurposed medications. Given that some of the medications are perceived to have low toxicity, many have been embraced without evidence. Although remdesivir was recently found to shorten time to symptom resolution, evidence for survival benefit is inconclusive

Item Type:	Article
Subjects:	QV Pharmacology > Drug Standardization. Pharmacognosy. Medicinal Plants > QV 771 Standardization and evaluation of drugs WA Public Health > WA 105 Epidemiology WC Communicable Diseases > WC 20 Research (General) WC Communicable Diseases > Virus Diseases > Viral Respiratory Tract Infections. Respirovirus Infections > WC 505 Viral respiratory tract infections
Digital Object Identifer (DOI):	https://doi.org/10.7326/M20-2933
Depositing User:	Stacy Murtagh
Date Deposited:	17 Jun 2020 11:50
Last Modified:	11 Dec 2020 02:02
URI:	https://archive.lstmed.ac.uk/id/eprint/14781

Statistics

View details

Actions (login required)

Edit Item